Lee S. Schwartzberg, MD, FACP, is medical director of the West Cancer Center and Research Institute, Professor of medicine at The University of Tennessee Health Science Center in Memphis, and served as the Chief of the Division of Hematology/Oncology in the Department of Medicine from 2012-2018. In 2019 he became founding Chief Medical Officer at OneOncology, a national oncology practice management and services organization. He maintains an active medical oncology practice. In his research career, he has published more than 260 manuscripts on breast cancer, precision oncology and supportive care and received an ASCO clinical trials participation award. Dr. Schwartzberg previously served on the National Comprehensive Cancer Network Board of Directors, its Guideline Steering Committee, and the Breast Cancer Guideline Panel, among others. He is past founding chairman of the Association of Community Cancer Centers Immuno-Oncology Institute and serves as the editor-in-chief of the Elsevier website PracticeUpdate Oncology.
The diagnosis, risk stratification, and treatment of cancer have become increasingly personalized. Clinicians utilize novel testing technologies to select targeted therapeutics based on predictive biomarkers. The advent of newer and less invasive approaches to diagnosis such as liquid biopsy is enabling clinicians to better tailor treatment plans for their patients. Novel immunotherapy agents used alone or in combination with other agents may further optimize outcomes for patients with advanced disease. This session will explore the unique challenges that community-based clinicians face in their practice.